TERSERA
SpecialtyTERSERA is a specialty pharmaceutical company focused on Oncology. Key products include VARUBI.
FDA Novel Drug Designations
(2017)See 1 novel approval →
TERSERA's Key Drugs
TERSERA's core commercial portfolio centers on VARUBI, XERMELO, spanning Oncology — its most strategically important drugs approved in the last 15 years.
TERSERA's Recent FDA Approvals
New NDA/BLA approvals for TERSERA over the last two years — novel drugs only, excluding generics and label supplements.
TERSERA's Therapeutic Areas
TERSERA's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
TERSERA's Top Competitors
TERSERA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
TERSERA Pipeline Snapshot
TERSERA has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • VARUBI leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling